# Summit Therapeutics Inc. Common Stock (SMMT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $17.61, market value $14.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Summit Therapeutics Inc. Common Stock reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 22.2×**. The shares trade at 22.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -3.3%** (5-yr avg -6.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -163.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -29.5%**. Each dollar of assets produces -29.5% of profit.

## Growth
- **EPS growth (1 yr): -364.5%**. Earnings per share fell 364.5%.

## Financial health
- **Interest coverage: -26.0×**. Operating profit covers interest only -26.0×: fragile.
- **Current ratio: 9.87** (quick 9.87). Current assets cover the next year's liabilities 9.87 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Summit Therapeutics Inc. Common Stock does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (13 analysts). 13 analysts cover Summit Therapeutics Inc. Common Stock; the consensus is buy, with an average price target of $28.40 (+61% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -26.0%** (YTD 0.7%, 3-mo 19.2%). The shares are down 26.0% over twelve months including dividends.
- **From 52-week high: -39.8%** (45.9% above the low). Trading 40% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 71**. An RSI of 71 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 1.63** (volatility 76%). Beta of 1.63 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SMMT · Page: https://foliofundamentals.com/stocks/smmt

Not investment advice.